- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01660607
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Phase 1-2 Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objectives:
- To determine the efficacy, safety and feasibility of administration of several dose combinations of conventional T cells (Tcon) and regulatory T cells (Treg) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) with HLA matched donors (related or unrelated) using a T cell depleted graft [CD34+ hematopoietic progenitor cells ("CD34+ HSPC")], without immune suppression.
- To determine the maximum tolerated dose of infused regulatory and conventional T cells in the matched donor setting
- To determine 1 year event free survival (EFS) post HCT
Secondary Objectives:
- To determine the 1 year OS in patients undergoing allogeneic HCT with matched donors.
- To measure the incidence and severity of acute and chronic graft vs host disease (GvHD)
- To measure incidence of serious infections
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States, 94305
- Stanford University School of Medicine Palo Alto, California, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Recipient Inclusion Criteria
Patients with the following diseases that are histopathologically confirmed are eligible
- Acute leukemia, primary refractory or beyond CR1, or minimal residual disease (MRD) positivity.
- High risk acute myeloid leukemia in CR1 with any of the following features:
- Complex karyotype(≥3 clonal chromosomal abnormalities)
Any of the following high risk chromosomal abnormalities:
- Monosomal karyotype (-5, 5q-, -7, 7q-)
- t(11q23), t(9;11), inv(3), t(3;3) t(6;9) t(9;22)
- Normal karyotype with fms-like tyrosine kinase 3 (FLT3)-ITD mutation
- Other high risk features as determined by molecular studies, or clinical presentation as assessed by the treating physician
- Chronic myelogenous leukemia (accelerated, blast or second chronic phase)
- Myelodysplastic syndromes
- Myeloproliferative syndromes
- Non-Hodgkin lymphoma with poor risk features not suitable for autologous HCT
- Age ≥18 yo and ≤ 60 yo for patients in Cohort 1 only. At the start of Cohort 2A and beyond, eligibility will be expanded to allow pediatric patients age ≥ 13 yo.
- Cardiac ejection fraction ≥ 45%
- Lung diffusion capacity ≥ 50%
- Calculated creatinine clearance ≥ 50 cc/min
- Serum glutamic-pyruvic transaminase( SGPT) and serum glutamic-oxaloacetic transaminase (SGOT) ≤ 3.0 x ULN (Upper limit of normal), unless elevated secondary to disease.
- Total bilirubin ≤ 2 x ULN (patients with Gilbert's syndrome may be included at the discretion of the PI or where hemolysis has been excluded
- Availability of a HLA matched donor (related or unrelated) defined by Class I (HLA-A and B) serologic typing (or higher resolution) and Class II (HLA DRB1) molecular typing. An HLA matched donor is defined for this study to be a sibling that is HLA matched 6/6; or an unrelated donor that is HLA matched 6/6 or 5/6. A sibling may be a "half sibling."
- Karnofsky performance status ≥70%
Recipient Exclusion Criteria
Seropositive for any of the following:
HIV ab; hepatitis B sAg; hepatitis C ab
- Prior myeloablative therapy or hematopoietic cell transplant
- Candidate for autologous transplant
- HIV positive
- Active uncontrolled bacterial, viral or fungal infection, defined as currently taking antimicrobial therapy and progression of clinical symptoms.
- Uncontrolled central nervous system (CNS) disease involvement
- Pregnant or a lactating female
- Positive serum or urine beta human chorionic gonadotropin (HCG) test in females of childbearing potential within 3 weeks of registration
- Psychosocial circumstances that preclude the patient being able to go through transplant or participate responsibly in follow up care
Donor Inclusion Criteria
- Age ≥13 yo and ≤ 75 years
- Karnofsky performance status of ≥ 70% defined by institutional standards
Seronegative for HIV 1 RNA (polymerase chair reaction (PCR); HIV 1 and HIV 2 ab (antibody); HTLV 1 and HTLV 2 ab; PCR+ or sAg (surface antigen) hepatitis B ; or PCR+ or sAg for hepatitis C; negative for the Treponema pallidum antibody Syphilis screen; and negative for HIV 1 and hepatitis C by nucleic acid testing (NAT) within 30 days of apheresis collection. In the case that T pallidum antibody tests are positive, donors must:
- Be evaluated and show no evidence of syphilis infection of any stage by physical exam and history
- Have completed effective antibiotic therapy to treat syphilis
- Have a documented negative non treponemal test (such as RPR) or in the case of a positive non treponemal test must be evaluated by an infectious disease expert to evaluate for alternative causes of test positivity and confirm no evidence of active syphilitic disease
- Must be 6/6 matched sibling donor as determined by HLA typing
- Female donors of child-bearing potential must have a negative serum or urine beta-HCG test within three weeks of mobilization
- Capable of undergoing leukapheresis, have adequate venous access, and be willing to undergo insertion of a central catheter should leukapheresis via peripheral vein be inadequate
- Agreeable to 2nd donation of Peripheral blood stem cell (PBPC) (or bone marrow harvest) in the event of graft failure
- The donor or legal guardian greater than 18 years of age, capable of signing an institutional review board (IRB-approved consent form.
Donor Exclusion Criteria
- Evidence of active infection or viral hepatitis
- HIV positive
- Medical, physical, or psychological reason that would place the donor at increased risk for complications from growth factor or leukapheresis
- Lactating female
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose escalation
For the Phase I arm of the study the addition of planned numbers and ratios of Treg compared to Tcon will occur at defined time points after hematopoietic cell infusion.
Each cohort will have 3 patients per group.
The initial doses and ratios utilized will be 1 x 10^6/kg of T reg cells to 3x10^6/kg of Tcon cells at a 1:3 ratio.
In order to progress to the next dose level, there must be no evidence of grade 3 or 4 acute GVHD.
|
A baseline cell dose of conventional T cells of 1x10^6/kg will be used with escalation to the maximum tolerated dose up to 1x10^7/kg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GvHD free Relapse free Survival (GRFS)
Time Frame: 12 months
|
GvHD-free is defined as no GvHD symptoms, and relapse free survival is defined as survival at 12 months without relapse.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting toxicity (DLT)
Time Frame: 28 days
|
Dose-limiting Toxicity (DLT) was assessed as:
|
28 days
|
Overall Survival (OS)
Time Frame: 1 year
|
Overall Survival (OS) at 1 year was assessed as the number of participants per treatment level that received the hematopoietic cell transplant (HCT), and remained alive 12 months later, a number without dispersion.
|
1 year
|
Incidence and Severity of Chronic GvHD
Time Frame: 2 years
|
Incidence and severity of chronic GvHD wil be assessed in participants who received the hematopoietic cell transplant (HCT). Stage of chronic GvHD was assessed as follows.
|
2 years
|
Incidence of Serious Infections
Time Frame: 24 months
|
The outcome is reported as the number of serious infections per treatment level, in participants who received the hematopoietic cell transplant (HCT), a number without dispersion.
|
24 months
|
Concomitant Single-agent Immunosuppression
Time Frame: 2 years
|
During Phase 2, stage 1, concomitant single-agent immunosuppression will be assessed as in participants receiving fresh Treg cells.
The outcome is reported as number of such participants who received single-agent immunosuppression, by treatment level, a number without dispersion.
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Everett Meyer, Stanford University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Disease
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Precancerous Conditions
- Leukemia, Lymphoid
- Lymphoma
- Chronic Disease
- Syndrome
- Myelodysplastic Syndromes
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lymphoma, Non-Hodgkin
- Preleukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Other Study ID Numbers
- IRB-21257
- SU-09142011-8407 (Other Identifier: Stanford University)
- BMT236 (Other Identifier: OnCore)
- 1R01HL114591-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Non-Hodgkin
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
Mayo ClinicNot yet recruitingIndolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
Clinical Trials on Conventional T cells (Tcon) and Regulatory T cells (Treg)
-
Laura JohnstonNational Institutes of Health (NIH)CompletedGraft Versus Host Disease | Allogeneic Hematopoietic Cell Transplant RecipientUnited States
-
Nanjing Medical UniversityUniversity of MinnesotaUnknownChronic Rejection of Liver TransplantChina
-
King's College LondonImperial College London; Medical Research Council; Guy's and St Thomas' NHS Foundation... and other collaboratorsUnknownCrohn Disease
-
University of Erlangen-Nürnberg Medical SchoolCompletedAutoimmune Diseases | Ulcerative ColitisGermany
-
Stanford UniversityWithdrawnCovid19 | Acute Respiratory Distress SyndromeUnited States
-
The Nordic Network For Clinical Islet TransplantationActive, not recruiting
-
Masonic Cancer Center, University of MinnesotaTerminatedFollicular Lymphoma | Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Lymphoma | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Acute Myelogenous Leukemia | Mantle-Cell Lymphoma | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia | Small... and other conditionsUnited States
-
King's College Hospital NHS TrustRecruiting
-
Nanjing Medical UniversityUnknown
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of ExcellenceTerminatedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States